Try our Advanced Search for more refined results
Life Sciences - December, 2013
220 articles
- Genzyme Puts Up $22M To Settle FCA Claims
- FDA Permits Last-Resort Iclusig Use After Clinical Trial Deaths
- The Gift That Keeps On Giving (To Defendants)
- US Recouped $3.8B From False Claims Settlements In 2013
- Pfizer Absolved In Quigley Asbestos Injury Suit
- CreAgri's Supplement Patent Invalidated For Lack Of Data
- SAC Manager Martoma's Request To Delay Trial Denied
- Deal Makers Close 2013 With String Of Big Pharma Plays
- Cephalon Sues Hetero Over Generic Leukemia Drug
- Deals Rumor Mill: Hard Rock, Evonik, Vivendi
- Merck Recalls Gardasil Over Glass Particles In Vials
- FDA Extends Comment Period On Generic Drugs Rule
- Female Powerbrokers Q&A: McCarter & English's Pam Moore
- Female Powerbrokers Q&A: Vorys Sater's Benita Kahn
- A Busy Year For Patent Eligibility: 6 Key Decisions
- Generic Fosamax Users Must Give More Details In MDL
- MicroMed Investors Say Execs Lied About Heart Pump Patents
- GNC Glucosamine False Ad Suits Combined In Md.
- Calif. High Court Says Prescription Fee Disclosure Law OK
- Landmark Chemicals Case May Embolden EPA
- Boehringer May Face More Sanctions In Pradaxa MDL
- Big Pharma At Crossroads After GSK Payment Reforms
- JPML Centralizes Glucosamine False Ad Suits
- Bayer Offers $2.9B For Cancer Drugmaker Algeta
- How They Won It: Greenberg Wins Stiefel Securities Verdict
- Unions Worry Over EU-US Trade Deal's Impact On Drug Costs
- AstraZeneca Puts Up $4.1B To Take Over Diabetes Drug JV
- Fed. Circ. Affirms Hanmi Win In Generic Nexium Patent Suit
- $4.75M Ferring, Aventis Antitrust Settlement Earns Approval
- Warner Chilcott Sues Torrent To Block Generic Enablex
- Female Powerbrokers Q&A: Novak Druce's Pat Rogowski
- Female Powerbrokers Q&A: White And Williams' Joan Rosoff
- Merck Unit Hit With €15.3M Competition Fine In France
- Blackstone Passes Indian Drugmaker Stake To Bain
- Post-Actavis, Pay-For-Delay Debate Is Far From Over
- Pain-Pump Seller DJO Lied To Get $10M Policy, Insurer Says
- Teva Hit With Securities Class Action Over CEO Resignation
- Stryker Inks 1st Settlements In NJ Hip Implant Suits
- J&J Fights Attys' Pursuit Of Confidential Risperdal Docs
- Allergan Hit With FCA Kickback Suit Over Eye Drugs
- Radient Pays $2.5M To End Claims It Lied About Mayo Clinic
- MLB Can Depose A-Rod's Cousin, Fla. Appeals Court Says
- Pfizer GC To Step Down Ahead Of Reshuffling
- 3rd Circ. Doubts Jurisdiction In Generic-Fosamax Appeal
- FDA, EMA To Share Generic Drug Inspection Duties
- Female Powerbrokers Q&A: Ober Kaler's Barbara Werther
- Female Powerbrokers Q&A: Dechert's Cathy Botticelli
- A Year Of Change For Life Sciences IP
- SAC Manager Can't Escape Charges Involving Foreign Stocks
- Pfizer Pay-For-Delay Claims Get 2nd Chance
- Life Sciences MVP: Fish & Richardson's Jonathan Singer
- Shook Hardy Reels In Litigation Pro For Orange County Office
- Diet Pill Maker, Snooki Face Suit Over Weight Loss Ads
- Eli Lilly Defeats Soldier's Cymbalta 'Brain Zap' Suit
- GSK To End Doctor Payments To Market Meds
- Female Powerbrokers Q&A: Locke Lord's Denise Hanna
- Female Powerbrokers Q&A: Morrison & Foerster's Anna White
- Spain's Almirall Pledges $400M For Skin Drug Co. Aqua
- 4th Circ. Questions Basis For Generic-Drug Injury Appeal
- Stryker Hip Implant Suit Stays In Federal MDL
- Pa. High Court Jettisons Wyeth's $9M Prempro Appeal
- Chinese Co. To Pay $2.2M To End Vitamin C Antitrust Case
- Life Sciences MVP: Kirkland's Jay Lefkowitz
- VC Firm Can't Collect $7.5M From Transvaginal Mesh Suits
- Lawmakers Float Bill To Ease New Antibiotic Approvals
- Teva Wins Ban On Mylan Parkinson's Generic
- Gov't Sees Outlier Among Off-Label Cases Under FCA
- Top 13 Product Liability Law Developments For 2013
- GSK Seeks To Up Stake In Indian Unit By $1B
- Cogent Ducks Fraud Suit Over Joint Pain Supplement
- Valeant Puts Up $250M For Struggling Solta Medical
- Female Powerbrokers Q&A: Arnold & Porter's Maureen Jeffreys
- Female Powerbrokers Q&A: Fish's Ann Cathcart Chaplin
- High Court Turns Down Teva Unit's Provigil Patent Appeal
- Fen-Phen Malpractice Awards Denied By Texas High Court
- 3rd Circ. Asked To Tackle Venue Dispute In Paxil Suit
- Life Sciences MVP: Morrison & Foerster's David Doyle
- Bankrupt Savient Gets OK For $120M Sale To Crealta
- Torrent Pharma To Pay $323M For Elder's Formulations Biz
- Biosimilars Can't Circumvent BPCIA With Litigation
- FDA Encouraged Illegal Compounding, K-V Tells DC Circ.
- Female Powerbrokers Q&A: Paul Hastings' Elizabeth Noe
- Female Powerbrokers Q&A: Bartlit's Rebecca Weinstein Bacon
- 5 Steps To A Successful Cross-Examination
- Irish High Court Approves Perrigo's $8.6B Elan Buy
- FDA Pushes Medical Device Self-Audit Pilot Program
- Life Sciences MVP: White & Case's Dimitrios Drivas
- 'All Natural' Food Claims: Back To Ad Law Basics
- Novartis Settles Patent Suit Over Organ Transplant Drug
- Chinese Scientists Attempted To Steal Seeds, DOJ Says
- Drugmakers Lose Bid For 'Indefinite' Extension In FTC Case
- AGs Urge FDA To Rethink High-Powered Painkiller Approval
- 4th Circ. Revives Purdue Pharma OxyContin FCA Row
- Female Powerbrokers Q&A: White And Williams' Patti Santelle
- Female Powerbrokers Q&A: Mayer Brown's Debora De Hoyos
- Roche, Prothena Form $600M Parkinson's Partnership
- Bankrupt Savient Takes $120M Bid From Pharma Co. Crealta
- Pharma Co. Investors Can Serve China Execs Via US Counsel
- Life Sciences MVP: Sullivan & Cromwell's Frank Aquila
- P&G Can't Bar Testimony In Fixodent Suit, 11th Circ. Hears
- FDA Pushes To Curb Antibiotic Use In Livestock
- FTC OKs Settlement With Actavis Over Warner Chilcott Buy
- Nexium Direct Purchasers Win Class Cert. In Antitrust MDL
- Weary Judges Urge Tort Attys To Rethink Longshot Motions
- Criticisms Mount On Drug IP Proposals In Pacific Trade Pact
- Fed. Circ. Won't Revive St. Jude Vascular Closure Patent
- How Iran Nuclear Deal May Impact US Medicine Exports
- Fed. Circ. Finds Galderma Acne Gel Patents Obvious In IP Row
- Stryker Fax Recipients Win Class Cert. In TCPA Suit
- Risperdal Plaintiffs Push For Release Of J&J Studies
- Female Powerbrokers Q&A: Morrison Cohen's Danielle Lesser
- Female Powerbrokers Q&A: Liner Grode's Angela Agrusa
- The Rise Of Predictive Coding For Life Sciences
- Invitae Wants Myriad's Gene-Testing Patent Suit Tossed
- Plaintiffs' Firm Wants Ex-Associate's Fee Claim Arbitrated
- Firm Says Novartis Whistleblower Owes Fees For Failed Suit
- FTC Tries Pulling Teva Into Cephalon Pay-For-Delay Suit
- NJ Hospital Gets Criminal Docs On Bristol-Myers Black Widow
- Align Technology, Execs Dodge Proposed Fraud Class Action
- Ex-Hansen Medical VP Can't Shake SEC's Fraud Claims
- CVS Caremark, Cardinal Health Form Generic Drug Supply JV
- Pa. Court Won't Reopen Fixodent Nerve-Damage Suit
- Female Powerbrokers Q&A: Akin Gump's Kerry Berchem
- Female Powerbrokers Q&A: Locke Lord's Cynthia Bast
- J&J, Novartis Fined $22.4M Over Pay-For-Delay Deal
- Deals Rumor Mill: Novartis, Siemens, Blackstone
- Elliott Threatens To Block $8.4B Celesio Takeover
- Pharmacy Wholesalers Escape Drug-Inflation FCA Suit
- Heart Health Co. Sues Rival Over Genetic Test Patent
- Boehringer Fined $1M For Withholding Docs In MDL
- Merck Settles Fosamax Jaw-Injury Claims For $28M
- Enzo Contract Claims Trimmed In Affymetrix Med Testing Row
- Who Knew That Aredia, Zometa Caused De Jaw Vu?
- AstraZeneca Can't Shake Patent Suit Over Crestor Trials
- FDA Faults Biogen Over Sterility, 'Questionable' Paperwork
- Justices Won't Touch Smith & Nephew's $85M Patent Win
- Orchid, MPI Dodge Enzo Biochem's Patent, Contract Claims
- Female Powerbrokers Q&A: Gibson Dunn's Mary Murphy
- Female Powerbrokers Q&A: Arnold & Porter's Veronica Rendon
- High Court Passes On Lupron Labeling Suit
- Covidien Shells Out $860M For Israeli Medical Co.
- Post To Shell Out Nearly $700M For Healthy Brands
- High Court Denies Bid To Review Neurontin RICO Rulings
- How FRCP E-Discovery Amendments Could Affect You
- Deals Rumor Mill: Occidental, KKR, Freedom Group
- Hologic Hands Icahn 2 Board Seats To Head Off Proxy Fight
- NJ Appeals Court Will Hear Nostrum Attys' Fee Fight
- Medtronic Escapes Jury's $18M Surgical Fire Verdict
- Warner Chilcott Can't Dodge Interference Claim In IP Row
- 1st Circ. Ends Takeda FCA Suit But Limits Scope Of Ruling
- Former Cancer Research Exec Indicted Over $11M Grant
- FCA Report Author Backs Proposed Reforms Over Objections
- J&J Keeps Vaginal Mesh Suit Out Of Texas State Court
- Purdue, Impax Settle IP Claims In OxyContin Antitrust MDL
- Orion, Novartis Settle Patent Dispute Over Sedation Drug
- Roche Asks Fed. Circ. To Revive Boniva Dosage Patents
- US Asks Court To Junk Medical Device Co.'s Contract Suit
- Female Powerbrokers Q&A: Debevoise's Peggy Davenport
- Female Powerbrokers Q&A: Reed Smith's Dusty Kirk
- How Fed. Circ.'s Commil Ruling Could Affect Drug Patents
- FDA Dings Drugmakers Over Missing Pediatric Studies
- Feds Raid Reckitt Benckiser Pharmaceuticals Office In Va.
- Medical Product Co. Liable For ACA Tax, Judge Says
- Bristol-Myers Escapes Abilify Movement Disorder Suit
- BMS Urges Fed. Circ. To Revive Hepatitis B Drug Patent
- Amphastar Sanctioned For Veiling Docs Over Blood Thinner IP
- Female Powerbrokers Q&A: Chadbourne's Lori Hoberman
- Female Powerbrokers Q&A: O'Melveny's Carla Christofferson
- Merck Shells Out $2.6B For Specialty Chemicals Maker
- How Plaintiffs' Forum Shopping Paid Off In Novartis Case
- Consumer Protection Laws And Prescription Meds: A Poor Fit
- Ametek Drops $128M On Power Management Systems Maker
- Auxilium Loses Testim Patent Claims Against Upsher-Smith
- Bowman Opens San Diego Office With Drug, Device Attys
- FDA Reaches $1.25M Deal Over Mislabeled ASP Products
- 'Difficult To Compound' Drug List Gets Revived By FDA
- FDA Revises Equivalence Criteria For Generic Drug Approval
- Pamlab Can't Bar Virtus' Marketing In Unfair Competition Row
- FDA Warns Of Possible Philips Defibrillator Failure
- Merck Sued For Securities Fraud Over Cholesterol Drug Trial
- Getinge Plans $189M Offer For Pulsion Medical Systems
- Female Powerbrokers Q&A: Hunton & Williams' Lisa Sotto
- Female Powerbrokers Q&A: Hogan Lovells' Emily Yinger
- Abbott Settles NY False Ad Case Over Children's Drinks
- Deals Rumor Mill: GM, Essex Property, Men's Wearhouse
- Medicines Co. Puts Up $474M For Specialty Drugmaker
- Exela Tries To Escape Ruling, Nix Painkiller Patent Again
- FDA Tells Wockhardt To Assess Drug Facilities
- Multinational Pharmas: Expect Key Policy Shifts In China
- A Crash Course In Hot Product Liability Topics
- And Now A Word From The Panel: Too Hot Or Cold For An MDL?
- Belgian Court Rules Herbalife Not Pyramid Scheme, Co. Says
- AstraZeneca Deserves $76M In Drug Patent Suit, Judge Says
- Biopharma Co. Sues UC, Temple Over Proprietary Disclosure
- How They Won It: Irell Nixes Patent For Prenatal DNA Test
- Lundbeck Seizure Drug Poses Serious Skin Risks, FDA Warns
- Skanska Lands $95M In Lab Sale To REIT
- Female Powerbrokers Q&A: K&L Gates' Janice Hartman
- Female Powerbrokers Q&A: JAMS' Kimberly Taylor
- Elliott Wants Major Influence Over Buyout Target Celesio
- Gallant Pharma Pleads Guilty In Black-Market Drug Case
- J&J Unit Accused Of Losing Key Docs In Vaginal Mesh MDL
- FDA Again Blasts Pfizer Unit Over Quality-Control Mishaps
- Fed. Circ. Mulls Standing In Univ. Of Wis. Stem Cell IP Row
- Hunton Atty's Drunk Remark Not Insider Trading, Court Hears
- 4 Little-Noticed FCA Rulings Attys Need To Know
- Shire Fires Back At Mylan's Grab For Docs In Patent Row
- Generic-Reglan Suits Doomed By Catch-22, 6th Circ. Says
- HeartWare Buys CircuLite In Deal That Could Reach $350M
- J&J Asks Pa. Court To Keep Risperdal Docs Under Seal
- 23andMe Hit With False Ad Suit Over DNA Tests
- Diageo Shells Out $81M To Settle Aussie, NZ Thalidomide Suits
- Idenix Suits Target Gilead Hep C Drug Nearing Approval
- FDA Urges Providers To Work With Registered Compounders
- Following Up On Follow-On Biologics
- Pa. Appeals Court Upholds GSK Win In Paxil Pregnancy Suit
- Standing Issue Threatens 15 Zometa Suits In NJ
- Female Powerbrokers Q&A: DLA Piper's Tara Lee
- Female Powerbrokers Q&A: Jones Day's Lizanne Thomas
- Mild Modifications To The R&D Tax Credit